Circumventing the heterogeneity and instability of human serum albumin-interferon-α2b fusion protein by altering its orientation

Journal of Biotechnology

Volumn 131, Issue 3, 2007, Pages 245-252

  Zhao, Hong Liang ^a   Xue, Chong ^a   Wang, Yang ^a   Li, Xian Yu ^a   Xiong, Xiang Hua ^a   Yao, Xue Qin ^a   Liu, Zhi Min ^a  

^a BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

Author keywords

Human serum albumin fusion protein; Long acting interferon; Pichia pastoris

Indexed keywords

DISEASES; GENES; MUTAGENESIS; PATIENT TREATMENT; PERTURBATION TECHNIQUES; SOLUTIONS;

GENETIC FUSION; HUMAN SERUM ALBUMIN FUSION PROTEINS; LONG ACTING INTERFERON; PICHIA PASTORIS;

PROTEINS;

ALBUMIN ALPHA INTERFERON; CYSTEINE; DISULFIDE;

AMINO TERMINAL SEQUENCE; AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; COVALENT BOND; DRUG FORMULATION; DRUG MECHANISM; DRUG SCREENING; DRUG STABILITY; DRUG STRUCTURE; GENETIC HETEROGENEITY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; NONHUMAN; PICHIA PASTORIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SERUM; SITE DIRECTED MUTAGENESIS; TEMPERATURE SENSITIVITY;

ANTIVIRAL AGENTS; DRUG DESIGN; DRUG STABILITY; HUMANS; INTERFERON ALFA-2B; PROTEIN CONFORMATION; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; SERUM ALBUMIN; VESICULAR STOMATITIS INDIANA VIRUS;

PICHIA PASTORIS;

EID: 34548393737     PISSN: 01681656     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2007.04.016     Document Type: Article

References (19)

1. Arakawa T., Prestrelski S.J., Narhi L.O., Boone T.C., and Kenney W.C. Cysteine 17 of recombinant human granulocyte-colony stimulating factor is partially solvent-exposed. J. Protein Chem. 12 5 (1993) 525-531
2. Bain V.G., Kaita K.D., Yoshida E.M., Swain M.G., Heathcote E.J., Neumann A.U., Fiscella M., Osborn B.L., Cronin P.W., Freimuth W.W., McHutchison J.G., and Subramanian G.M. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J. Hepatol. 44 (2006) 671-678
3. Duttaroy A., Kanakaraj P., Osborn B.L., Schneider H., Pickeral O.K., Chen C., Zhang G.Y., Kaithamana S., Singh M., Schulingkamp R., Crossan D., Bock J., Kaufman T.E., Reavey P., Barber M.C., Krishnan S.R., Garcia A., Murphy K., Siskind J.K., McLean M.A., Cheng S., Ruben S., Birse C.E., and Blondel O. Development of long-acting insulin analog using albumin fusion technology. Diabetes 54 (2005) 251-258
4. Esposito D., Gillette W.K., Miller D.A., Taylor T.E., Frank P.H., Hu R., Bekisz J., Hernandez J., Cregg J.M., Zoon K.C., and Hartley J.L. Gateway cloning is compatible with protein secretion from Pichia pastoris. Protein Exp. Purif. 40 2 (2005) 424-428
5. Foster G.R. Interferons in host defense. Semin. Liver Dis. 17 (1997) 287-295
6. Grace M.J., Lee S., Bradshaw S., Chapman J., Spond J., Cox S., DeLorenzo M., Brassard D., Wylie D., Carlson S.C., Cullen C., Indelicato S., Voloch M., and Bordens R. Site of pegylation and polyethylene glycol molecule size attenuate interferon-α antiviral and antiproliferative activities through the JAK/STAT signaling pathway. J. Biol. Chem. 280 8 (2005) 6327-6336
7. Grace M.J., Youngster S., Gitlin G., Sydor W., Xie L., Westreich L., Jacobs S., Brassard D., Bausch J., and Bordens R. Structural and biologic characterization of pegylated recombinant IFN-alpha2b. J. Interferon Cytokine Res. 21 12 (2001) 1103-1115
8. Gutterman J.U. Cytokine therapeutics: Lessons from interferon α. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 1198-1205
9. Halpern W., Riccobene T.A., Agostini H., Baker K., Stolow D., Gu M.L., Hirsch J., Mahoney A., Carrell J., Boyd E., and Grzegorzewski K.J. Albugranin Trade Mark, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys. Pharm. Res. 19 11 (2002) 1720-1729
10. Liu P.T., Ta T.V., and Villarete L.H. High-yield expression and purification of human interferon-α1 in Pichia pastoris. Protein Exp. Purif. 22 (2001) 381-387
11. Osborn B.L., Olsen H.S., Nardelli B., Murray J.H., Zhou J.X.H., Garcia A., Moody G., Zaritskaya L.S., and Sung C. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-α fusion protein in cynomolgus monkeys. J. Pharmacol. Exp. Ther. 303 (2002) 540-548
12. Osborn B.L., Sekut L., Corcoran M., Poortman C., Sturm B., Chen G.X., Mather D., Lin H.L., and Parry T.J. Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys. Euro. J. Pharmacol. 456 (2002) 149-158
13. Reddy K.R., Modi M.W., and Pedder S. Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C. Adv. Drug Deliv. Rev. 54 (2002) 571-584
14. Sugio S., Kashima A., Mochizuki S., Noda M., and Kobayashi K. Crystal structure of human serum albumin at 2,5 A resolution. Protien Eng. 12 6 (1999) 439-446
15. Syed S., Schuyler P.D., Kulczycky M., and Sheffield W.P. Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin. Blood 89 9 (1997) 3243-3253
16. Wang W., Ou Y., and Shi Y.G. AlbuBNP, a recombinant B-type natriuretic peptide and human serum albumin fusion hormone, as a long-term therapy of congestive heart failure. Pharm. Res. 21 11 (2004) 2105-2111
17. Wang Y.S., Yongster S., Grace M., Bausch M., Bordens R., and Wyss D.F. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic applications. Adv. Drug Deliv. Rev. 54 (2002) 547-570
18. Way J.C. Second-generation protein drugs: children of the revolution. Drug Discov. World Winter 3 (2002) 62-68
19. Yeh P., Landais D., Lemaitre M., Maury I., Crenne J.Y., Becquart J., Murry B.A., Boucher F., Montay G., and Fleer R. Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 1904-1908